MP CARDIO-B-NEW Reports Annual Loss Widening by 170.85% to $18.819 Million

Stock News

Mar 31

MP CARDIO-B-NEW (02160) announced its annual results for the period ending December 31, 2025. The company reported revenue of $57.044 million, representing a 12.28% year-on-year increase. However, the loss attributable to shareholders was $18.819 million, a significant expansion of 170.85% compared to the previous year. The basic loss per share was $0.04.

According to the announcement, the growth in revenue was primarily driven by income generated from the CRM business following the consolidation of MicroPort® Rhythm Management effective December 19, 2025. Additionally, overseas revenue from the structural heart disease business saw rapid growth, increasing by 255.0% compared to the fiscal year ending December 31, 2024. This surge was attributed to the ongoing global commercialization efforts for the VitaFlow Liberty® and Alwide® Plus product lines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1164912858"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164912858\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164912858?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 00:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164912858","market":"sh","top_or_hot":-1,"title":"MP CARDIO-B-NEW Reports Annual Loss Widening by 170.85% to $18.819 Million","media":"Stock News","content":"<p>MP CARDIO-B-NEW (02160) announced its annual results for the period ending December 31, 2025. The company reported revenue of $57.044 million, representing a 12.28% year-on-year increase. However, the loss attributable to shareholders was $18.819 million, a significant expansion of 170.85% compared to the previous year. The basic loss per share was $0.04.</p>\n<p>According to the announcement, the growth in revenue was primarily driven by income generated from the CRM business following the consolidation of MicroPort® Rhythm Management effective December 19, 2025. Additionally, overseas revenue from the structural heart disease business saw rapid growth, increasing by 255.0% compared to the fiscal year ending December 31, 2024. This surge was attributed to the ongoing global commercialization efforts for the VitaFlow Liberty® and Alwide® Plus product lines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MP CARDIO-B-NEW Reports Annual Loss Widening by 170.85% to $18.819 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMP CARDIO-B-NEW Reports Annual Loss Widening by 170.85% to $18.819 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-31 00:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MP CARDIO-B-NEW (02160) announced its annual results for the period ending December 31, 2025. The company reported revenue of $57.044 million, representing a 12.28% year-on-year increase. However, the loss attributable to shareholders was $18.819 million, a significant expansion of 170.85% compared to the previous year. The basic loss per share was $0.04.</p>\n<p>According to the announcement, the growth in revenue was primarily driven by income generated from the CRM business following the consolidation of MicroPort® Rhythm Management effective December 19, 2025. Additionally, overseas revenue from the structural heart disease business saw rapid growth, increasing by 255.0% compared to the fiscal year ending December 31, 2024. This surge was attributed to the ongoing global commercialization efforts for the VitaFlow Liberty® and Alwide® Plus product lines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1225","symbol_name":"钢铁","start_time":0,"source_url":"","article_id":"1164912858","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164912858","pubTimestamp":1774889658,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MP CARDIO-B-NEW (02160) announced its annual results for the period ending December 31, 2025. The company reported revenue of $57.044 million, representing a 12.28% year-on-year increase. However,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1225":"钢铁","BK1583":"高瓴概念","BK1239":"汽车零售","BK1100":"医疗保健设备","02160":"微创心通-B","02918":"微创心通-B","BK1574":"生物医药B类股"},"translate_title":"MP CARDIO-B-NEW报告年度亏损扩大170.85%至1881.9万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1,"02918":1},"content_text":"MP CARDIO-B-NEW (02160) announced its annual results for the period ending December 31, 2025. The company reported revenue of $57.044 million, representing a 12.28% year-on-year increase. However, the loss attributable to shareholders was $18.819 million, a significant expansion of 170.85% compared to the previous year. The basic loss per share was $0.04.\nAccording to the announcement, the growth in revenue was primarily driven by income generated from the CRM business following the consolidation of MicroPort® Rhythm Management effective December 19, 2025. Additionally, overseas revenue from the structural heart disease business saw rapid growth, increasing by 255.0% compared to the fiscal year ending December 31, 2024. This surge was attributed to the ongoing global commercialization efforts for the VitaFlow Liberty® and Alwide® Plus product lines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}